ג'נואט 50 מג500 מג ישראל - עברית - Ministry of Health

ג'נואט 50 מג500 מג

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - טבליה - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 500 mg - metformin - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ג'נואט 50 מג850 מג ישראל - עברית - Ministry of Health

ג'נואט 50 מג850 מג

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - טבליה - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 850 mg - metformin - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

טרג'נטה דואו 2.5 מג500 מג ישראל - עברית - Ministry of Health

טרג'נטה דואו 2.5 מג500 מג

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - טבליות מצופות פילם - metformin hydrochloride 500 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

טרג'נטה דואו 2.5 מג850  מג ישראל - עברית - Ministry of Health

טרג'נטה דואו 2.5 מג850 מג

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

טרג'נטה דואו 2.5 מג1000 מג ישראל - עברית - Ministry of Health

טרג'נטה דואו 2.5 מג1000 מג

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - טבליות מצופות פילם - linagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.

קומפטקט 15 מג  850 מג ישראל - עברית - Ministry of Health

קומפטקט 15 מג 850 מג

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

אוויסטה ישראל - עברית - Ministry of Health

אוויסטה

eli lilly israel ltd, israel - raloxifene hydrochloride - טבליות מצופות פילם - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - evista is indicated for the treatment of osteoporosis in post menopausal women. evista is indicated for the prevention of osteoporosis in post menopausal women . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

אלפו-קל XL ישראל - עברית - Ministry of Health

אלפו-קל xl

padagis israel agencies ltd, israel - alfuzosin hydrochloride - טבליות בשחרור ממושך - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason.

טרזוסין טבע    5 מג ישראל - עברית - Ministry of Health

טרזוסין טבע 5 מג

teva pharmaceutical industries ltd, israel - terazosin as hydrochloride dihydrate - טבליה - terazosin as hydrochloride dihydrate 5 mg - terazosin - terazosin - for symptomatic treatment of urinary obstructon caused by benign prostatic hyperplasia (bph). for mild to moderate hypertension.

טרזוסין טבע    2 מג ישראל - עברית - Ministry of Health

טרזוסין טבע 2 מג

teva pharmaceutical industries ltd, israel - terazosin as hydrochloride dihydrate - טבליה - terazosin as hydrochloride dihydrate 2 mg - terazosin - terazosin - for symptomatic treatment of urinary obstructon caused by benign prostatic hyperplasia (bph). for mild to moderate hypertension.